Cabozantinib potential option to treat differentiated thyroid cancer

14 Feb 2018


According to results that will be presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium in Arizona this Friday, tumours treated with the drug shrunk in 97% of patients.

Science Daily


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story